Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 462

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia

Open access
Foà, Robin, Vitale, Antonella, Vignetti, Marco, Meloni, Giovanna, Guarini, Anna, De Propris, Maria Stefania, Elia, Loredana, Paoloni, Francesca, Fazi, Paola, Cimino, Giuseppe, Nobile, Francesco, Ferrara, Felicetto, Castagnola, Carlo, Sica, Simona, Leoni, Pietro, Zuffa, Eliana, Fozza, Claudio, Luppi, Mario, Candoni, Anna, Iacobucci, Ilaria, Soverini, Simona, Mandelli, Franco, Martinelli, Giovanni, Baccarani, Michele, on behalf of the GIMEMA Acute Leukemia Working Party·2011·Blood
DOI 10.1182/blood-2011-05-351403
Open this paper in CoChat — free account

Abstract

Dasatinib is a potent BCR-ABL inhibitor effective in chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia (ALL) resistant/intolerant to imatinib. In the GIMEMA LAL1205 protocol, patients with newly diagnosed Ph+ ALL older than 18 years (with no upper age limit) received dasatinib induction therapy for 84 days combined with steroids for the first 32 days and intrathecal chemotherapy. Postremission therapy was free. Fifty-three patients were evaluable (median age, 53.6 years). All patients achieved a complete hematologic remission (CHR), 49 (92.5%) at day 22. At this time point, 10 patients achieved a BCR-ABL reduction to < 10−3. At 20 months, the overall survival was 69.2% and disease-free survival was 51.1%. A significant difference in DFS was observed between patients who showed at day 22 a decrease in BCR-ABL levels to < 10−3 compared with patients who never reached these levels during induction. In multivariate analysis, BCR-ABL levels of < 10−3 at day 85 correlated with disease-free survival. No deaths or relapses occurred during induction. Twenty-three patients relapsed after completing induction. A T315I mutation was detected in 12 of 17 relapsed cases. Treatment was well tolerated; only 4 patients discontinued therapy during the last phase of the induction when already in CHR. In adult Ph+ ALL, induction treatment with dasatinib plus steroids is associated with a CHR in virtually all patients, irrespective of age, good compliance, no deaths, and a very rapid debulking of the neoplastic clone. This trial was registered at www.clinicaltrials.gov as #NCT00391989.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2011-05-351403

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 50 references

Cited by

See all 462

Metadata

Authors
Foà, R., Vitale, A., Vignetti, M., Meloni, G., Guarini, A., De Propris, M. S., Elia, L., Paoloni, F., Fazi, P., Cimino, G., Nobile, F., Ferrara, F., Castagnola, C., Sica, S., Leoni, P., Zuffa, E., Fozza, C., Luppi, M., Candoni, A., Iacobucci, I., Soverini, S., Mandelli, F., Martinelli, G., Baccarani, M., & Party, O. B. O. T. G. A. L. W.
Venue
Blood
Publisher
American Society of Hematology
Published
2011-12-15
Volume
118
Issue
25
Pages
6521-6528
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
DOI
10.1182/blood-2011-05-351403
OpenAlex
W2065851457
Cited by
462
References
50
FWCI
24.40
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. https://app.cochat.ai/papers/10.1182/blood-2011-05-351403
The paper
Foà, R., Vitale, A., Vignetti, M., Meloni, G., Guarini, A., De Propris, M. S., Elia, L., Paoloni, F., Fazi, P., Cimino, G., Nobile, F., Ferrara, F., Castagnola, C., Sica, S., Leoni, P., Zuffa, E., Fozza, C., Luppi, M., Candoni, A., . . . Party, O. B. O. T. G. A. L. W. (2011). Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. Blood. https://doi.org/10.1182/blood-2011-05-351403

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.